Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 11/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | CCNK | O75909 | 1/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29994379 | 1.00 | RIPK1 (0.60) | RIPK1HRH4HRH3DAOCNR2 | |
| SCHEMBL296469 | 0.84 | HRH4 (0.57) | RIPK1HRH4HRH3DAOCNR2 | |
| SCHEMBL13808700 | 0.83 | KDM4E (0.59) | RIPK1HRH4HRH3DAOCNR2 | |
| SCHEMBL28696362 | 0.83 | CNR2 (0.57) | RIPK1HRH4HRH3DAOCNR2 | |
| Hydrochloric Acid SCHEMBL1878102 | 0.83 | HRH4 (0.56) | RIPK1HRH4HRH3DAOCNR2 | |
| SCHEMBL4271585 | 0.80 | HRH4 (0.57) | RIPK1HRH4HRH3DAOCNR2 | |
| SCHEMBL15848423 | 0.80 | RIPK1 (0.62) | RIPK1HRH4HRH3DAOCNR2 | |
| SCHEMBL31088687 | 0.80 | HRH4 (0.57) | RIPK1HRH4HRH3DAOCNR2 | |
| Hydrochloric Acid SCHEMBL1879831 | 0.79 | HRH4 (0.56) | RIPK1HRH4HRH3DAOCNR2 | |
| SCHEMBL18181380 | 0.79 | HRH4 (0.56) | RIPK1HRH4HRH3DAOCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | claimed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | claimed |
| EP-4182323-B1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | claimed |
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | claimed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | claimed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | claimed |
| EP-2699576-A1 | PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2014-02-26 | — | — | EP | claimed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | claimed |
| WO-2012143813-A1 | PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-10-26 | — | — | WO | claimed |
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| EP-2235016-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | claimed |
| EP-2235015-A2 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | claimed |
| WO-2009112679-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | claimed |
| WO-2009112678-A2 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | claimed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | claimed |
| CN-101166739-A | Substituted pyrrolopyridines, compositions containing them, process for their preparation and their use | AVENTIS PHARMA SA (FR) | 2008-04-23 | — | — | CN | claimed |
| EP-1877409-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-01-16 | — | — | EP | claimed |
| EP-1771448-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2007-04-11 | — | — | EP | claimed |
| WO-2006114520-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-11-02 | — | — | WO | claimed |
| WO-2006050976-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, IDO1 | RIPK1 2088/4885HRH4 121/4885HRH3 152/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | RIPK1 249/4885HRH4 1081/4885HRH3 1127/4885 |
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | SDHA, ALDH5A1, SDHB | RIPK1 3536/4885HRH4 582/4885HRH3 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.